Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06474533 · ClinicalTrials.gov registry record
Fluoroethyltyrosine for the Evaluation of Intracranial Neoplasm
A clinical trial of Intracranial Neoplasm, sponsored by Thomas Hope.
- Recruiting
- Registry status
- 199
- Enrollment target
- 1
- Study location
NCT06474533 is a study of Intracranial Neoplasm that is actively recruiting participants, run by Thomas Hope. The registered enrollment target is 199 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06474533, a study of Intracranial Neoplasm, is actively recruiting participants, sponsored by Thomas Hope.
- RECRUITING
- Registry status
- 199 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a single center study investigating the use of Fluoroethyltyrosine (FET) in the detection of brain tumors. FET accumulates in malignant cells within intracranial neoplasms and can be used to detect recurrent disease and characterize grade of glial neoplasms.
Conditions Studied
Interventions
- PROCEDURE Positron Emission Tomography (PET)
- DRUG Fluorethyltyrosine (18-F)
Study Locations (1)
California
- University of California, San Francisco - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 199 participants |
| Start Date | 2024-06-21 |
| Est. Completion | 2028-08-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06474533
The ClinicalTrials.gov registry entry for NCT06474533 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 199 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Thomas Hope, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Intracranial Neoplasm appearing as the primary indexed condition, and to 2 interventions - of which Positron Emission Tomography (PET) is the first listed.
NCT06474533 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT06474533 about?
NCT06474533 is a clinical study titled "Fluoroethyltyrosine for the Evaluation of Intracranial Neoplasm". This is a single center study investigating the use of Fluoroethyltyrosine (FET) in the detection of brain tumors. FET accumulates in malignant cells within intracranial neoplasms and can be used to detect recurrent disease and characterize grade of glial neoplasms.
What is the current status of trial NCT06474533?
This trial is currently recruiting. The enrollment target is 199 participants. The study started on 2024-06-21. Estimated completion is 2028-08-31.
What conditions does trial NCT06474533 study?
This clinical trial studies the following conditions: Intracranial Neoplasm.
What interventions are being tested in trial NCT06474533?
The interventions under investigation include: Positron Emission Tomography (PET) (PROCEDURE), Fluorethyltyrosine (18-F) (DRUG).
Who is sponsoring clinical trial NCT06474533?
This trial is sponsored by Thomas Hope, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06474533 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Intracranial Neoplasm
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.